Suppr超能文献

土耳其转移性结直肠癌患者中KRAS突变的区域和性别分布:一项观察性研究。

Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study.

作者信息

Ilhan Nurullah, Dane Faysal, Goker Erdem, Uygun Kazım, Orhan Bülent, Okutur Kerem, Ünek İlkay Tuğba, Işıkdoğan Abdurrahman, Bilici Ahmet, Zengin Nurullah, Alkış Necati, Yücel İdris, Odabaş Hatice, Öksüzoğlu Berna Ömür, Doğan Akif, Erölmez Hande Nur, Gümüş Mahmut

机构信息

Department of Medical Oncology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, 34785 Istanbul, Turkey.

Department of Medical Oncology, Faculty of Medicine, Marmara University, 34865 Istanbul, Turkey.

出版信息

Medicina (Kaunas). 2025 Apr 10;61(4):694. doi: 10.3390/medicina61040694.

Abstract

KRAS genes are among the most prominent oncogenes that trigger tumor formation in colorectal cancer (CRC) and serve as predictive biomarkers for resistance to anti-EGFR therapies in metastatic colorectal cancer (mCRC) patients. However, the prevalence and mutation spectrum of the KRAS gene family in mCRC patients in Turkey have not been sufficiently analyzed. This study investigates the frequency and distribution of mutations in the KRAS gene family across different regions of Turkey and examines gender-related variations. This multicenter observational study included 2458 histologically confirmed mCRC patients collected from 52 centers across Turkey. In a central laboratory, KRAS mutations in codons 12 and 13 were analyzed using polymerase chain reaction (PCR). Statistical analyses were performed using chi-square tests and Monte Carlo simulations, with a significance threshold set at < 0.05. Depending on the region, KRAS mutations were detected in 45% of patients, ranging from 39.6% to 47.5%. The mutation rate was significantly higher in female patients (48.8%) compared to male patients (42.6%) ( = 0.002). Codon 12 mutations were more frequent than codon 13 mutations. G12D, G12V, and G13D mutations accounted for 80% of all detected mutations. The G12V mutation was prevalent in female patients ( = 0.007). Based on region, mutation diversity was similar, and no statistically significant difference was found ( > 0.05). This large-scale, multicenter study provides the most comprehensive dataset of KRAS mutations in mCRC patients in Turkey. This study revealed regional trends, as well as gender differences. The findings highlight the importance of routine KRAS genotyping in guiding personalized treatment strategies, especially regarding candidate selection for anti-EGFR therapies. Further research is required to elucidate the prognostic and therapeutic implications of specific KRAS mutations.

摘要

KRAS基因是引发结直肠癌(CRC)肿瘤形成的最主要致癌基因之一,也是转移性结直肠癌(mCRC)患者抗表皮生长因子受体(EGFR)治疗耐药性的预测生物标志物。然而,土耳其mCRC患者中KRAS基因家族的患病率和突变谱尚未得到充分分析。本研究调查了土耳其不同地区KRAS基因家族突变的频率和分布,并研究了性别相关差异。这项多中心观察性研究纳入了从土耳其52个中心收集的2458例经组织学确诊的mCRC患者。在一个中心实验室,使用聚合酶链反应(PCR)分析第12和13密码子的KRAS突变。采用卡方检验和蒙特卡罗模拟进行统计分析,显著性阈值设定为<0.05。根据地区不同,45%的患者检测到KRAS突变,范围从39.6%到47.5%。女性患者的突变率(48.8%)显著高于男性患者(42.6%)(P = 0.002)。第12密码子突变比第13密码子突变更常见。G12D、G12V和G13D突变占所有检测到突变的80%。G12V突变在女性患者中更为普遍(P = 0.007)。基于地区,突变多样性相似,未发现统计学显著差异(P>0.05)。这项大规模、多中心研究提供了土耳其mCRC患者中最全面的KRAS突变数据集。本研究揭示了地区趋势以及性别差异。这些发现凸显了常规KRAS基因分型在指导个性化治疗策略中的重要性,尤其是在抗EGFR治疗的候选选择方面。需要进一步研究以阐明特定KRAS突变的预后和治疗意义。

相似文献

本文引用的文献

6
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.KRAS 突变对结直肠癌肿瘤微环境的影响。
Int J Biol Sci. 2024 Mar 3;20(5):1947-1964. doi: 10.7150/ijbs.88779. eCollection 2024.
9
KRAS inhibition in metastatic colorectal cancer: An update.转移性结直肠癌的 KRAS 抑制:更新。
Curr Opin Pharmacol. 2023 Feb;68:102343. doi: 10.1016/j.coph.2022.102343. Epub 2023 Jan 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验